AstraZeneca India receives permission from DCGI for Dapagliflozin
The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca
The approval allows treatment of heart failure patients irrespective of the ejection fraction based on new trial DELIVER conducted by AstraZeneca
The two-part production system is proven to yield high-quality proteins from GS-CHO cell lines, a prevalent mammalian host cell for protein production
LITFULO is the first and only treatment for severe alopecia areata approved for patients as young as 12
The booster vaccine can be administered safely to individuals who have received two doses of either Covaxin or Covishield
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
The collaboration focuses on the development and sharing of Standard Quality and Regulatory Documentation (StaQRD), a standard guide for the electronic transfer of information
The judicial response to industry lawsuits on drug pricing regulations have been mixed in the past
Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe
Subscribe To Our Newsletter & Stay Updated